Agenus Crescita futura
Criteri Future verificati 0/6
Si prevede che gli utili di Agenus diminuiranno del 59.7% all'anno, mentre si prevede che il fatturato annuo crescerà del 2.4% all'anno. Si prevede che l'EPS diminuirà del 70.2% all'anno.
Informazioni chiave
-59.7%
Tasso di crescita degli utili
-70.20%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 29.0% |
| Tasso di crescita dei ricavi | 2.4% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 11 Aug 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Aug 15
AGEN: Refocused Colorectal Cancer Pipeline And Funding Will Support Future Upside
Agenus sees its analyst fair value estimate move from $30.00 to $19.50 as analysts recalibrate long term assumptions on revenue growth, profitability and future P/E, following recent price target changes related to financing plans and the refocused pipeline. Analyst Commentary Recent Street research on Agenus highlights a mix of optimism about the refocused pipeline and caution around financing and execution.
Aggiornamento narrativa • Jul 31
AGEN: Refocused Colon Cancer Program And New Funding Will Drive Upside
Agenus is in focus after analysts lifted their price target to $14 from $8, citing a revised view on fair value, updated growth and margin assumptions, and a higher future P/E multiple following recent research that highlights the company’s refocused oncology pipeline and $340M private placement. Analyst Commentary on Agenus Recent research on Agenus highlights a mix of optimism around the oncology pipeline and the US$340M private placement, alongside some clear areas where analysts see meaningful execution and valuation risks.Aggiornamento narrativa • Jul 13
AGEN: Neoadjuvant Colorectal Cancer Focus And Funding Will Drive Bullish Reassessment
Agenus' analyst price target has been reset from $15.50 to $30.00. Analysts point to the company's refocus on botensilimab and balstilimab in neoadjuvant microsatellite stable colorectal cancer, as well as the recently announced $340.0m private placement, as key drivers of their updated view.Aggiornamento narrativa • Jun 23
AGEN: Late-Stage Cancer Pipeline And Access Programs Will Drive Future Upside
Analysts have revised their price target on Agenus to reflect a lower assumed future P/E of 24.80x, down from 34.01x, alongside updated views on revenue growth and profit margins that together temper growth expectations while assuming a stronger profitability profile. What’s in the News for Agenus Agenus is advancing its botensilimab plus balstilimab program with new retrospective data using Noetik’s AI based TARIO-2 model to analyze routine H&E tumor images and identify spatial tumor microenvironment patterns linked with clinical outcomes in solid tumors, including microsatellite stable metastatic colorectal cancer, ovarian cancer, and sarcomas, with results to be presented at the 2026 ASCO Annual Meeting.Aggiornamento narrativa • Jun 08
AGEN: Phase 3 Colorectal Cancer Trial Will Support Bullish Reassessment
Analyst price targets for Agenus have been reaffirmed at $15.50, with modest adjustments to the discount rate, revenue growth assumptions, profit margin and forward P/E reflecting analysts' updated view of the stock's risk profile and earnings potential. What's in the News Agenus is advancing its botensilimab plus balstilimab (BOT+BAL) program with multiple data disclosures, including new Phase 2 results in advanced cutaneous melanoma and published Phase 1b data in treatment refractory hepatocellular carcinoma.Aggiornamento narrativa • May 24
AGEN: Phase 3 Colorectal Cancer Trial Will Drive Bullish Reassessment
Analysts now set a higher price target for Agenus, moving their fair value estimate from $12.33 to $15.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Phase 2 data from the C-800-23 study in advanced cutaneous melanoma showed a 22% confirmed objective response rate for botensilimab plus balstilimab, with median overall survival of 16.6 months and a 42% 2 year overall survival rate in the overall cohort, and no treatment related deaths reported (Key Developments).Aggiornamento narrativa • May 04
AGEN: Late Stage Cancer Data And Access Programs Will Drive Future Upside
Analysts have reduced their price targets on Agenus by $8.00 after updating their assumptions for revenue growth, profit margins, and future P/E levels to reflect a more conservative view of the stock’s valuation inputs. What's in the News Agenus is presenting four botensilimab and balstilimab abstracts at the 2026 ASCO Annual Meeting, including first Phase 2 data in advanced cutaneous melanoma and a trial-in-progress update on the Phase 3 CO.33/BATTMAN colorectal cancer study (Key Developments).Aggiornamento narrativa • Apr 20
AGEN: Late Stage Gastrointestinal Cancer Data Will Drive Future Upside
Analysts have nudged their price target on Agenus higher to $8.00, reflecting updated assumptions around discount rates, revenue trends, profit margins, and future P/E expectations. What's in the News Agenus reported Phase II data from a Memorial Sloan Kettering trial combining botensilimab, balstilimab, agenT-797, ramucirumab, and paclitaxel in advanced PD-1 refractory gastroesophageal adenocarcinoma, with a 77% disease control rate in 17 patients and a subset showing survival beyond 20 months (AACR Annual Meeting 2026).Aggiornamento narrativa • Apr 04
AGEN: Expanded Late-Stage Trials And Access Programs Will Drive Future Upside
Analysts have raised their price target on Agenus from $6.00 to $8.00. This reflects updated assumptions around fair value, discount rate, revenue growth, profit margin, and a higher future P/E of 28.67x compared with 19.01x previously.Aggiornamento narrativa • Aug 17
Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care
The notable upward revision in Agenus’s fair value target is primarily driven by significant improvements in net profit margin and a modest increase in forecasted revenue growth, resulting in a consensus analyst price target increase from $11.00 to $12.33. What's in the News Agenus' botensilimab and balstilimab immunotherapy programs continue to show promising clinical progress, with new survival data and presentations at major oncology congresses, including a 42% two-year survival rate and 21-month median OS in immunotherapy-resistant MSS metastatic colorectal cancer.
Nuova narrativa • Apr 08
BOT/BAL Trials And Cost Reductions Will Shape Future Advances
Strategic cost reduction and asset monetization aim to strengthen financials and fund key projects like BOT/BAL, enhancing potential revenues and earnings.Seeking Alpha • Jul 24
Agenus: Novel Drugs That Just Are Not Novel
Summary Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock performance and financial struggles. The company's primary assets in its pipeline are Botensilimab and Balstilimab, which have shown limited efficacy in pre-clinical and clinical trials. Recent FDA meeting and phase 2 metastatic colorectal cancer data plummeted AGEN stock 60%, due to discouragement to file for accelerated approval. Further funding is likely to be required soon, considering high cash burn rates and the upcoming phase 3 trial in mCRC. Read the full article on Seeking AlphaArticolo di analisi • May 21
There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
Agenus Inc. ( NASDAQ:AGEN ) shareholders are no doubt pleased to see that the share price has bounced 102% in the last...Articolo di analisi • May 09
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
Shareholders might have noticed that Agenus Inc. ( NASDAQ:AGEN ) filed its quarterly result this time last week. The...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 128 | -50 | -44 | N/A | 2 |
| 12/31/2027 | 137 | -26 | -20 | N/A | 2 |
| 12/31/2026 | 140 | 35 | 7 | N/A | 1 |
| 6/30/2026 | 133 | 92 | -99 | -99 | N/A |
| 3/31/2026 | 124 | 64 | -88 | -88 | N/A |
| 12/31/2025 | 114 | 0 | -77 | -77 | N/A |
| 9/30/2025 | 107 | -35 | -89 | -89 | N/A |
| 6/30/2025 | 102 | -166 | -128 | -128 | N/A |
| 3/31/2025 | 100 | -191 | -146 | -146 | N/A |
| 12/31/2024 | 103 | -227 | -159 | -158 | N/A |
| 9/30/2024 | 160 | -228 | -171 | -170 | N/A |
| 6/30/2024 | 160 | -224 | -186 | -182 | N/A |
| 3/31/2024 | 161 | -240 | -212 | -204 | N/A |
| 12/31/2023 | 156 | -246 | -234 | -224 | N/A |
| 9/30/2023 | 101 | -271 | -255 | -231 | N/A |
| 6/30/2023 | 99 | -263 | -234 | -198 | N/A |
| 3/31/2023 | 95 | -240 | -232 | -182 | N/A |
| 12/31/2022 | 98 | -220 | -228 | -175 | N/A |
| 9/30/2022 | 90 | -215 | -199 | -151 | N/A |
| 6/30/2022 | 320 | 18 | -42 | 13 | N/A |
| 3/31/2022 | 310 | -19 | -38 | 0 | N/A |
| 12/31/2021 | 296 | -24 | -24 | 10 | N/A |
| 9/30/2021 | 307 | 4 | -28 | -3 | N/A |
| 6/30/2021 | 69 | -226 | -170 | -166 | N/A |
| 3/31/2021 | 85 | -190 | -150 | -147 | N/A |
| 12/31/2020 | 88 | -181 | -143 | -139 | N/A |
| 9/30/2020 | 91 | -174 | -139 | -135 | N/A |
| 6/30/2020 | 97 | -168 | -135 | -131 | N/A |
| 3/31/2020 | 85 | -171 | N/A | -130 | N/A |
| 12/31/2019 | 150 | -108 | N/A | -19 | N/A |
| 9/30/2019 | 122 | -126 | N/A | -23 | N/A |
| 6/30/2019 | 115 | -113 | N/A | -19 | N/A |
| 3/31/2019 | 115 | -87 | N/A | -14 | N/A |
| 12/31/2018 | 37 | -160 | N/A | -131 | N/A |
| 9/30/2018 | 39 | -147 | N/A | -121 | N/A |
| 6/30/2018 | 29 | -151 | N/A | -123 | N/A |
| 3/31/2018 | 18 | -158 | N/A | -120 | N/A |
| 12/31/2017 | 43 | -121 | N/A | -94 | N/A |
| 9/30/2017 | 40 | -112 | N/A | -84 | N/A |
| 6/30/2017 | 41 | -116 | N/A | -82 | N/A |
| 3/31/2017 | 44 | -113 | N/A | -73 | N/A |
| 12/31/2016 | 23 | -127 | N/A | -80 | N/A |
| 9/30/2016 | 25 | -117 | N/A | -83 | N/A |
| 6/30/2016 | 27 | -89 | N/A | -78 | N/A |
| 3/31/2016 | 27 | -101 | N/A | -72 | N/A |
| 12/31/2015 | 25 | -88 | N/A | -47 | N/A |
| 9/30/2015 | 19 | -98 | N/A | -38 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che gli utili di AGEN diminuiranno nei prossimi 3 anni ( -59.7% all'anno).
Guadagni vs Mercato: Si prevede che gli utili di AGEN diminuiranno nei prossimi 3 anni ( -59.7% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di AGEN diminuiranno nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di AGEN ( 2.4% all'anno) crescerà più lentamente rispetto al mercato US ( 13.4% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di AGEN ( 2.4% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di AGEN è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/14 13:59 |
| Prezzo dell'azione a fine giornata | 2026/09/14 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Agenus Inc. è coperta da 7 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Michael King | Citizens JMP Securities, LLC |
| Emily Bodnar | H.C. Wainwright & Co. |